Intracranial Arteriovenous Malformation
No Results
No Results
processing….
Abnormalities of the vascular structures of the head and brain have long been recognized. McCormick published an influential classification system in “The Pathology of Vascular (‘Arteriovenous’) Malformations.” [1] He described the arteriovenous malformation (AVM), cavernous malformation, venous malformation, telangiectasia, and varix. Intracranial varices are not of significant current clinical concern. This overview focuses on the previous 4 classes.
See the image below.
Luschka and Virchow originally described arteriovenous malformations (AVMs) in the mid 1800s. Olivecrona performed the first surgical excision in 1932. Lesions of the cerebral vasculature develop such that blood flows directly from the arterial system to the venous system without passing through a capillary system. The arteriovenous (AV) shunt is the definitive characteristic of these lesions. The estimated incidence of AVM in the US general population is 0.14% (140 cases per 100,000 persons or 1 case per 700 persons). This is approximately one fifth to one seventh the incidence of intracranial aneurysms.
One or more persisting direct connections from the arterial to the venous systems are present. AVMs are considered congenital lesions and are characterized by a failure of the embryonic vascular plexus to fully differentiate and develop a mature capillary bed in the affected area. The formation of AVMs probably relates to sequential formation and resorption of cerebral surface veins. Their structures may change and grow postnatally but only in relation to a prenatally extant lesion. Molecular biologic factors are thought to be important to AVM development. These may include vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Tissues adjacent to the AVM may be persistently mildly hypoxic because the malformation may steal blood from adjacent healthy tissue, further promoting angiogenesis.
The direct connection between the arterial and venous systems supplies a low-resistance shunt for arterial blood and exposes the venous system to abnormally high pressures. This results in a system of enlarged feeding vessels, the tangled nidus of the AVM itself, and enlarged draining venous structures.
Clinical presentation of AVM includes the following:
Hemorrhage (53% of cases): acute onset of severe headache, may be described as the worst headache of the patient’s life, depending on the location of hemorrhage, may be associated with new fixed neurologic deficit
Seizure (46%)
Headache (34%)
Progressive neurologic deficit (21%): may be caused by mass effect or ischemia resulting from local vascular steal phenomenon, presence and nature of deficit depend on location of lesion
Pediatric patients: heart failure, macrocephaly, prominent scalp veins
Hemorrhage is more likely to be caused by small lesions, while seizures are more likely to be caused by large lesions. An increasing number of lesions now are found incidentally upon brain imaging.
The annual risk of intracranial hemorrhages associated with AVMs is 2-3%. The mortality rate associated with the initial bleed is 10%. The mortality rate associated with the second bleed is 13%, and the rate increases to 20% for each subsequent bleed. The incidence of new neurologic deficit occurring with each bleed is 50%. These numbers are generalized for all AVMs. The location and size of each patient’s lesion greatly affects their risk of morbidity and mortality.
Patients with an AVM have an increased risk of developing a cerebral aneurysm. Approximately 7.6% of patients with an AVM develop an aneurysm. Alternatively, 1.1% of patients with an aneurysm are found to have an AVM. Most commonly, aneurysms are found on arteries feeding the AVM.
Rare case reports describe multiple intracranial AVMs and/or concomitant intracranial and intraspinal AVMs, but these are too rare to be well characterized. AVMs may present as part of a neurocutaneous syndrome, including Sturge-Weber syndrome or Rendu-Osler-Weber syndrome.
Workup for AVM includes the following:
Lab studies (these are for routine preoperative evaluation and not for diagnosis, per se): CBC count, prothrombin time (PT)/activated partial thromboplastin time (aPTT), typing, screening
CT scan is the first imaging choice in an emergent setting in which a patient is thought to have an intracranial bleed. It is fast and widely available.
CT angiography provides better vascular detail than MRI or magnetic resonance angiography (MRA), and can be performed in most emergency rooms. It can be a useful non-invasive alternative to cerebral angiography.
MRI is the first imaging choice in a nonemergency setting (eg, workup of seizure, headache, or neurologic deficit). It provides significantly greater resolution and flexibility in diagnosis. MRAs can reveal the anatomy of the AVM noninvasively but have lower resolution than conventional angiography and do not provide functional information. MRI is useful compared to computed tomoangiography (CTA) or cerebral angiography in that it provides better visualization of the surrounding cerebral structures. Functional MRI can assist in treatment planning by defining the functionality of adjacent brain. [2]
Cerebral angiography provides definitive diagnosis. It documents a functional AV shunt; however, because it is an invasive test, it is not performed as the first imaging study. Cerebral angiography also allows grading of the AVM via the following Spetzler and Martin criteria.
The Spetzler-Martin grading system (described in Table 1, below) helps predict the likelihood of satisfactory outcome if an attempt at surgical resection is made. The Spetzler-Martin grade is determined by adding the 3 individual scores from the table. High-grade AVMs are more difficult to resect, and, therefore, neurologic deficits from the surgery itself are more likely. Other grading systems have been proposed for radiosurgery planning.
A supplemental Spetzler-Martin grading system has been created that includes factors such as patient age, hemorrhagic presentation, nidal diffuseness, and deep perforating artery supply. It has been shown in some studies to have high predictive value of neurologic outcome after AVM surgery. [3, 4, 5]
The Spetzler Martin grading system leaves a great deal of variety, particularly in the Grade 3 type AVMs. Lawton proposed a supplemental grading scale to the classic Spetzler-Martin system to aid in treatment of middle grade AVMs. [6]
Table 1 . Spetzler-Martin Grading System for AVMs (Open Table in a new window)
Size of AVM*
Eloquence of adjacent brain†
Pattern of venous drainage‡
Small (< 3 cm)
1
Noneloquent
0
Superficial only
0
Medium (3-6 cm)
2
Eloquent
1
Deep component
1
Large (>6 cm)
3
…
…
* Measure the largest diameter of the nidus of the lesion on angiography.
† Eloquent areas include sensorimotor, language, visual, thalamus, hypothalamus, internal capsule, brain stem, cerebellar peduncles, and deep cerebellar nuclei.
‡ The lesion is considered superficial only if all drainage is via the cortical drainage system.
The Lawton supplemental Spetzler-Martin grading scale is as follows:
Age younger than 20 years – 1 point
Age 20-40 years – 2 points
Age older than 40 years – 3 points
Unruptured – 0 points
Ruptured – 1 point
Not diffuse – 0 points
Diffuse – 1 point
Vessel-selective 4-dimensional magnetic resonance angiography (VS-4D-MRA) has been shown to be a useful technique for evaluating of intracranial AVMs, especially for detecting feed arteries and estimating details of the nidus structure. One study showed detectability of feeding arteries by VS-4D-MRA was significantly higher than those of time-of-flight MRA and non-vessel-selective 4D-MRA. [2]
Trials directly comparing treatment approaches are lacking, and information on outcomes derives largely from case series. Complete obliteration is the goal of treatment as partial obliteration does not affect the rate of hemorrhage. Treatment includes the following:
Surgery (craniotomy)
Advantages: Cure is immediate and permanent after complete resection by craniotomy. Surgery is generally recommended for grade 1, 2, and 3 lesions, sometimes for grade 4 lesions, and not for grade 5 lesions.
Disadvantages: The potential for significant intraoperative bleeding, damage to adjacent neural tissue, and ischemic stroke are disadvantages. The “arteries of passage” supply intact neural tissue and must not be destroyed while attempting to interrupt the arterial supply to the AVM. A risk also exists for perfusion-breakthrough bleeding (ie, hemorrhage into the healthy part of the brain caused by sudden hemodynamic shifts), which results from the removal of a large AV shunt and the subsequent increased flow to previously underperfused vessels. Reports of rates of permanent neurologic deficit range from 0-15%, while mortality rates are close to zero in Spetzler-Martin grades 1-3 AVMs. Much higher morbidity and mortality rates are reported with grades 4-5 AVMs.
Endovascular neurosurgery (obliterating vessels with glues or particles delivered via arterial catheter in the angiography suite)
Advantages: Significant reduction of pathologic blood flow through the lesion can be achieved. Its main use is as adjuvant therapy prior to craniotomy to decrease intraoperative bleeding and technical difficulty. It has also been used to decrease the size of an AVM to make it sufficiently compact for effective targeting by stereotactic radiosurgery. Embolization may be curative in lesions less than 1 cm in diameter that are fed by a single artery. Improved obliteration rates of approximately 20% have been reported when using the embolic agent Onyx.
Disadvantages: This is an invasive procedure, and its major risks are similar to those for open surgery, ie, ischemia and hemorrhage. The main risk is causing ischemic stroke by occluding a feeding vessel that also supplies normal brain. Postembolization hemodynamic alterations can cause rupture of the AVM, resulting in new neurologic deficit from subarachnoid and/or intraparenchymal hemorrhage, analogous to the perfusion-breakthrough bleeding described above. This technique is not normally used by itself, as it rarely achieves complete eradication of the lesion and the pathologic vessels usually recanalize over time.
Stereotactic radiosurgery
Advantages: Stereotactic radiosurgery is noninvasive and can access all anatomic locations of the brain. New techniques available include staged radiosurgery for larger lesions (Grade IV and V), which has promising results.
Disadvantages: It is used to treat smaller lesions (< 3 cm in diameter) and requires 2 or more years for a full destructive effect. [7] The risk for hemorrhage is not reduced during this lag time. The risks of radiation necrosis of adjacent healthy tissue or cyst formation also exist. The cure rates for lesions smaller than 3 cm range from 81-90%. Therefore, a small subset of these lesions still hemorrhage after treatment.
The current gold standard for assessing AVM obliteration after stereotactic radiosurgery is digital subtraction angiography (DSA). In one study, MRI/MRA predicted AVM obliteration after SRS in most patients, but DSA should still be performed to confirm AVM nidus obliteration after SRS. [8]
Integration of 3-dimensional rotational angiography into stereotactic radiosurgery treatment planning was recently reported. Conti et al reported that this volumetric angiographic study can be integrated into computer-based treatment planning and offers a superior 3-dimensional view as a result of high spatial resolution. This technique allows a better 3-dimensional understanding of the target volume and distribution of the radiation doses within the volume. Further developments in the temporal resolution and the development of software tools to improve the performance of 3-dimensional contouring are necessary. [9]
Combination therapy
Total eradication of the lesion may require more than one modality. Partial treatment may increase the risk of hemorrhage.
Endovascular neurosurgery can be performed before surgical excision to reduce the difficulty of surgery or before radiosurgery to bring the size of the lesion to within the limits of the machine.
Radiosurgery may be used to eradicate small residual disease left after craniotomy (due to technical difficulty or involvement of eloquent structures).
Aneurysms associated with AVM
Aneurysms on an artery that does not feed the AVM can be managed as any unruptured intracranial aneurysm.
Aneurysms less than 5 mm in size have been reported to regress after treatment of AVM; in other cases, they have ruptured after treatment.
Given concern about aneurysms greater than 5 mm, treatment via microsurgical clipping or endovascular coiling is generally done prior to the treatment of the AVM.
Prognosis for untreated AVMs has been reported to include either a 2-3% or a 4% (depending on study cited) risk of bleeding per year, with an approximate 10% mortality rate associated with the bleed. Some studies suggest a 1% yearly mortality risk. The yearly combined major morbidity and mortality risk has been reported to be 2.7%. This figure includes only new clearly fixed neurologic deficits. It does not include other problems, such as seizures, personality changes, or memory disturbances, which also may have a significant disabling impact on the patient’s life and functioning.
Risks of conservative management and surgical intervention vary dramatically depending on the location and specific characteristics of individual lesions, which must be considered when applying this data to each patient.
Typically, attempts should be made to completely eradicate the lesion. Regardless of which method or combination of methods is used for treatment, eradication is considered definitive and recurrence is not a concern (except in occasional reports in the pediatric population).
Outcomes for patients with a subarachnoid hemorrhage caused by an AVM are better than outcomes for patients with a subarachnoid hemorrhage caused by an aneurysm. Outcome studies suggest that most patients return to full preoperative psychosocial function.
Multidisciplinary teams likely will become increasingly important for optimal management of each individual patient. Such teams may include neurosurgeons, interventional neuroradiologists, and stereotactic radiation specialists. Continuing advances in microsurgical, neurointerventional, and radiosurgical techniques will affect approaches to treatment. Algorithms guiding whether to treat or follow particular lesions will evolve. Advances in the efficacy and safety of the available interventions may emerge. Patients’ individual psychological factors will remain critical. For every patient, the immediate risks of intervention versus the likelihood of cure must be balanced.
Results of a randomized trial were published after early termination of the study. [10] The results indicated a significantly higher risk of stroke with disability and seizures in the intervention/surgical treatment group. The results of this study should be interpreted cautiously because of its poor enrollment; also, a small number of patients actually had surgical resection (n=5) or combined embolization with surgical resection (n=12), compared with endovascular embolization alone (n=30), or radisurgery (n=15). Clearly, these treatment modalities are not comparable, and surgical resection is usually curative compared to embolization and or radiosurgery.
It is important to evaluate each patient with an arteriovenous malformation on a case by case basis, weighing the risks of various treatment modalities versus the risks of the patient having a symptomatic hemorrhage and deciding what is best for each individual patient.
Cavernous angiomas are also known as cavernous hemangiomas or cavernomas. They can occur anywhere in the central nervous system. Occurrence is usually sporadic, but a significant proportion of cavernous angiomas are familial. These lesions were thought to be rare until the advent of MRI. They have since been identified in 0.5-1.0% of the population.
Three autosomal dominant genes are associated with the familial form. The precise function of these gene products are not known. They are as follows:
ccm1 on 7q chromosome and expresses KRIT1
ccm2 on 7p chromosome and expresses MGC4607
ccm3 on 3q chromosome and expresses PCD10
Cavernous angiomas consist of enlarged capillaries with characteristics as follows:
Sinusoidal
Single layer of endothelium
Thin collagenous wall
Lack of smooth muscle fibers and elastic fibers
Capillaries are immediately adjacent to each other, with no intervening neural tissue. They typically are not associated with enlarged feeding arteries or draining veins, and blood flow is low or even stagnated. Grossly, they may range from soft to hard. Thrombosis, calcification, or ossification results in a harder lesion.
Hallmark pathologic appearance is as follows::
Blood leakage (This results in hemosiderin staining; iron salts may incite an epileptogenic focus.)
Gliotic reaction in the adjacent brain
One review of the literature reported the following incidences among those lesions that become symptomatic:
Seizure (39%)
Hemorrhage (32%)
Mass effect (29%)
A significant percentage of lesions are asymptomatic, although accurately determining the frequency of asymptomatic lesions is difficult. Studies indicate that one tenth to one quarter of lesions are symptomatic. New research is suggesting that certain immune responses may be associated with proliferation and hemorrhage of cavernous malformations.
Occurrence generally is sporadic. One study revealed increased prevalence in Mexican American families, who also are more likely to have multiple lesions.
Lesions may be demonstrated on brain imaging studies, as follows:
CT scans may show focal hyperdensity, reflecting calcification or recent hemorrhage or mass effect, and intravenous contrast may show faint enhancement.
Cerebral angiograms demonstrate no vascular abnormalities. Although 8% of developmental venous anomalies have an associated cavernoma, which can be seen on angiography.
MRI scans reveal well-defined lesions on T1 and T2 sequences with sensitivity and specificity nearing 100%. The hemosiderin ring is visualized on a T2 sequence. Blood products of various ages can be observed in the center, and local edema may be present. [11]
Surgical removal eliminates mass effect and hemorrhage risk. It also removes the seizure focus. When the lesion is in a surgically accessible location, surgical removal can often be accomplished with relative ease and minimal risk. Functional MRI scans preoperatively may make resection safer. Brainstem cavernomas can be resected if the lesion reaches a pial surface. Currently, the role of radiosurgery is still debatable due to lack of follow-up studies and a reliable method to detect active lesion on radiographic examinations.
One study showed a 0.7% annual hemorrhage rate in cases of lesions followed prospectively. This rate increases dramatically if lesion enlargement within one year is documented. The estimated lifetime risk for hemorrhage, epilepsy, and other neurological sequelae are 50-70%. Intractable seizures, increase in lesion size on MRI, and an incident of gross hemorrhage are indications for removal of surgically accessible lesions.
Symptomatic lesions are likely to remain symptomatic or progress, but patients treated surgically experience remission or a reduction of symptoms. Approximately 50% of patients experience elimination of seizures, and the remainder have a decreased frequency of seizures. Elimination of seizures is more likely if the patient has not had seizures for many years. Successfully excised lesions are considered cured, and recurrence is not a concern.
The venous angioma, also known as a developmental venous anomaly, is the most common type of intracranial vascular malformation, as determined by incidental findings at autopsy. One autopsy study estimated a prevalence of 2.6%.
Pathologically, a venous angioma is an enlarged collection of veins. The architecture is essentially normal, except for the size. The veins receive drainage from adjacent healthy tissues. The veins appear as a radial arrangement, all converging on an enlarged central venous trunk. This trunk drains into healthy superficial or deep venous systems. No interruption of physiologic drainage occurs; therefore, the lesions are considered anomalies rather than pathological structures. Venous angiomas are postcapillary structures and are not associated with abnormal arteries.
Venous angiomas frequently are incidental radiographic findings, although some patients may present with intracranial hemorrhage. Patients also may present with a seizure or focal neurologic deficit. Posterior fossa lesions are more likely to result in a deficit.
Angiograms usually have a “hydra” or caput medusae appearance, resulting from the image of smaller radial veins converging on a central draining venous trunk. CT scan or MRI reveals a curvilinear structure that is described as resembling the spokes of a wheel. CT scans also may reveal a rounded enhancing area. MRI images may have sufficient resolution to reveal the caput medusae form.
Venous angioma has either no or very low risk of hemorrhage. Generally, patients are completely asymptomatic, and their cases should be followed conservatively.
Excision or ablation of venous angiomas is avoided. The angioma may be part of normal venous drainage for adjacent healthy neural tissue. Therefore, excision can lead to venous infarction of this tissue and significant morbidity and mortality.
Because many lesions are clinically silent and likely to escape diagnosis, comparing the natural history and associated prognosis of treated lesions versus untreated lesions is difficult.
Importantly, venous angiomas have been postulated to be pathophysiologically related to cavernous angiomas. In the case of a hemorrhage associated with a venous angioma, investigate for an adjacent cavernous angioma. If a cavernous angioma is found, resect the clot and the cavernous angioma, but do not resect the venous angioma.
The presence of capillary vessels with saccular or fusiform dilations characterizes capillary telangiectasias. These vessels lack muscular and elastic components in their walls. They are intercalated among healthy brain parenchyma. They are not associated with gliosis. Typically, no evidence of associated hemorrhage is present. Upon gross inspection, they are tiny lesions having the appearance of punctate hemorrhages.
Capillary telangiectasias almost always are clinically silent and not detectable radiographically. They are found incidentally on autopsy. Clinically significant intracranial hemorrhage has been reported very rarely.
These lesions may be related pathologically to cavernous angiomas. Some recommend considering the 2 as a single entity, referred to as capillary malformation.
Most capillary telangiectasias are clinically silent and are found incidentally on autopsy. Rare anecdotal reports of substantial hemorrhage exist. Previously, these lesions were undetectable radiographically. However, they may be visualized as a tiny area of hypointensity on T2-weighted MRI scans. These hypodensities may represent previous subclinical hemorrhage.
No treatment is indicated.
Importantly, capillary telangiectasias have been postulated to be pathophysiologically related to cavernous angiomas. Transitional forms with vessel histology sharing features of each entity have been described.
McCormick WF. The pathology of vascular (“arteriovenous”) malformations. J Neurosurg. 1966 Apr. 24(4):807-16. [Medline].
Fujima N, Osanai T, Shimizu Y, Yoshida A, Harada T, Nakayama N, et al. Utility of noncontrast-enhanced time-resolved four-dimensional MR angiography with a vessel-selective technique for intracranial arteriovenous malformations. J Magn Reson Imaging. 2016 Mar 10. [Medline].
Kim H, Abla AA, Nelson J, McCulloch CE, Bervini D, Morgan MK, et al. Validation of the supplemented Spetzler-Martin grading system for brain arteriovenous malformations in a multicenter cohort of 1009 surgical patients. Neurosurgery. 2015 Jan. 76 (1):25-31; discussion 31-2; quiz 32-3. [Medline].
Kim H, Pourmohamad T, Westbroek EM, McCulloch CE, Lawton MT, Young WL. Evaluating performance of the spetzler-martin supplemented model in selecting patients with brain arteriovenous malformation for surgery. Stroke. 2012 Sep. 43 (9):2497-9. [Medline].
Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery. 2010 Apr. 66 (4):702-13; discussion 713. [Medline].
Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL. A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. Neurosurgery. 2010 Apr. 66(4):702-13; discussion 713. [Medline].
Kano H, Lunsford LD, Flickinger JC, Yang HC, Flannery TJ, Awan NR, et al. Stereotactic radiosurgery for arteriovenous malformations, Part 1: management of Spetzler-Martin Grade I and II arteriovenous malformations. J Neurosurg. 2012 Jan. 116(1):11-20. [Medline].
Lee CC, Reardon MA, Ball BZ, Chen CJ, Yen CP, Xu Z, et al. The predictive value of magnetic resonance imaging in evaluating intracranial arteriovenous malformation obliteration after stereotactic radiosurgery. J Neurosurg. 2015 Jul. 123 (1):136-44. [Medline].
Conti A, Pontoriero A, Faragò G, et al. Integration of three-dimensional rotational angiography in radiosurgical treatment planning of cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys. 2011 Nov 1. 81(3):e29-37. [Medline].
Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014 Feb 15. 383(9917):614-21. [Medline].
Kim BS, Sarma D, Lee SK, Terbrugge KG. Brain edema associated with unruptured brain arteriovenous malformations. Neuroradiology. 2009 Feb 15. [Medline].
Baraitser M. The genetics of neurological disorders. London, United Kingdom: Oxford University Press; 1982.
Batjer H, Suss RA, Samson D. Intracranial arteriovenous malformations associated with aneurysms. Neurosurgery. 1986 Jan. 18(1):29-35. [Medline].
Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007 Oct 15. 16 Spec No. 2:R140-9. [Medline].
Cannestra AF, Pouratian N, Forage J, et al. Functional magnetic resonance imaging and optical imaging for dominant-hemisphere perisylvian arteriovenous malformations. Neurosurgery. 2004 Oct. 55(4):804-12; discussion 812-4. [Medline].
Del Curling O Jr, Kelly DL Jr, Elster AD, et al. An analysis of the natural history of cavernous angiomas. J Neurosurg. 1991 Nov. 75(5):702-8. [Medline].
Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet. 2002 Mar 9. 359(9309):863-73. [Medline].
Friedlander RM. Clinical practice. Arteriovenous malformations of the brain. N Engl J Med. 2007 Jun 28. 356(26):2704-12. [Medline].
Friedman WA, Bova FJ. Linear accelarator radiosurgery for arteriovenous malformations.
Friedman WA, Bova FJ, Mendenhall WM. Linear accelerator radiosurgery for arteriovenous malformations: the relationship of size to outcome. J Neurosurg. 1995 Feb. 82(2):180-9. [Medline].
Guidetti B, Delitala A. Intracranial arteriovenous malformations. Conservative and surgical treatment. J Neurosurg. 1980 Aug. 53(2):149-52. [Medline].
Hamilton MG, Spetzler RF. The prospective application of a grading system for arteriovenous malformations. Neurosurgery. 1994 Jan. 34(1):2-6; discussion 6-7. [Medline].
Heros RC, Korosue K, Diebold PM. Surgical excision of cerebral arteriovenous malformations: late results. Neurosurgery. 1990 Apr. 26(4):570-7; discussion 577-8. [Medline].
Heros RC, Morcos J, Korosue K. Arteriovenous malformations of the brain. Surgical management. Clin Neurosurg. 1993. 40:139-73. [Medline].
Jafar JJ, Awad IA, Rosenwasser RH. Vascular Malformations of the Central Nervous System. Lippincott Williams and Wilkins; 1999. 229-230.
Maruyama K, Kawahara N, Shin M, et al. The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med. 2005 Jan 13. 352(2):146-53. [Medline].
Miyamoto S, Hashimoto N, Nagata I, et al. Posttreatment sequelae of palliatively treated cerebral arteriovenous malformations. Neurosurgery. 2000 Mar. 46(3):589-94; discussion 594-5. [Medline].
Mohr JP. A randomized trial of unruptured brain arteriovenous malformations (ARUBA). Acta Neurochir Suppl. 2008. 103:3-4. [Medline].
Mullan S, Mojtahedi S, Johnson DL, et al. Embryological basis of some aspects of cerebral vascular fistulas and malformations. J Neurosurg. 1996 Jul. 85(1):1-8. [Medline].
Ogilvy CS, Stieg PE, Awad I, et al. AHA Scientific Statement: Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke. 2001 Jun. 32(6):1458-71. [Medline].
Ondra SL, Troupp H, George ED, et al. The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment. J Neurosurg. 1990 Sep. 73(3):387-91. [Medline].
Otten P, Pizzolato GP, Rilliet B, et al. [131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies]. Neurochirurgie. 1989. 35(2):82-3, 128-31. [Medline].
Pan HC, Sheehan J, Stroila M, et al. Late cyst formation following gamma knife surgery of arteriovenous malformations. J Neurosurg. 2005 Jan. 102 Suppl:124-7. [Medline].
Perret G, Nishioka H. Report on the cooperative study of intracranial aneurysms and subarachnoid hemorrhage. Section VI. Arteriovenous malformations. An analysis of 545 cases of cranio-cerebral arteriovenous malformations and fistulae reported to the cooperative study. J Neurosurg. 1966 Oct. 25(4):467-90. [Medline].
Pikus HJ, Beach ML, Harbaugh RE. Microsurgical treatment of arteriovenous malformations: analysis and comparison with stereotactic radiosurgery. J Neurosurg. 1998 Apr. 88(4):641-6. [Medline].
Pollock BE, Flickinger JC. A proposed radiosurgery-based grading system for arteriovenous malformations. J Neurosurg. 2002 Jan. 96(1):79-85. [Medline].
Redekop G, TerBrugge K, Montanera W, et al. Arterial aneurysms associated with cerebral arteriovenous malformations: classification, incidence, and risk of hemorrhage. J Neurosurg. 1998 Oct. 89(4):539-46. [Medline].
Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med. 1988 Aug 11. 319(6):343-7. [Medline].
Rigamonti D, Johnson PC, Spetzler RF, et al. Cavernous malformations and capillary telangiectasia: a spectrum within a single pathological entity. Neurosurgery. 1991 Jan. 28(1):60-4. [Medline].
Rigamonti D, Spetzler RF, Drayer BP, et al. Appearance of venous malformations on magnetic resonance imaging. J Neurosurg. 1988 Oct. 69(4):535-9. [Medline].
Rigamonti D, Spetzler RF, Medina M, et al. Cerebral venous malformations. J Neurosurg. 1990 Oct. 73(4):560-4. [Medline].
Robinson JR Jr, Awad IA, Magdinec M, et al. Factors predisposing to clinical disability in patients with cavernous malformations of the brain. Neurosurgery. 1993 May. 32(5):730-5; discussion 735-6. [Medline].
Robinson JR Jr, Awad IA, Masaryk TJ, et al. Pathological heterogeneity of angiographically occult vascular malformations of the brain. Neurosurgery. 1993 Oct. 33(4):547-54; discussion 554-5. [Medline].
Robinson JR, Awad IA, Little JR. Natural history of the cavernous angioma. J Neurosurg. 1991 Nov. 75(5):709-14. [Medline].
Rothbart D, Awad IA, Lee J, et al. Expression of angiogenic factors and structural proteins in central nervous system vascular malformations. Neurosurgery. 1996 May. 38(5):915-24; discussion 924-5. [Medline].
Senegor M, Dohrmann GJ, Wollmann RL. Venous angiomas of the posterior fossa should be considered as anomalous venous drainage. Surg Neurol. 1983 Jan. 19(1):26-32. [Medline].
Shenkar R, Shi C, Check IJ, et al. Concepts and hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations. Neurosurgery. 2007 Oct. 61(4):693-702; discussion 702-3. [Medline].
Simard JM, Garcia-Bengochea F, Ballinger WE Jr, et al. Cavernous angioma: a review of 126 collected and 12 new clinical cases. Neurosurgery. 1986 Feb. 18(2):162-72. [Medline].
Sirin S, Kondziolka D, Niranjan A, et al. Prospective staged volume radiosurgery for large arteriovenous malformations: indications and outcomes in otherwise untreatable patients. Neurosurgery. 2006 Jan. 58(1):17-27; discussion 17-27. [Medline].
Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986 Oct. 65(4):476-83. [Medline].
Svien HJ, McRae JA. Arteriovenous anomalies of the brain. Fate of patients not having definitive surgery. J Neurosurg. 1965 Jul. 23(1):23-8. [Medline].
Söderman M, Andersson T, Karlsson B, et al. Management of patients with brain arteriovenous malformations. Eur J Radiol. 2003 Jun. 46(3):195-205. [Medline].
Taylor CL, Dutton K, Rappard G, et al. Complications of preoperative embolization of cerebral arteriovenous malformations. J Neurosurg. 2004 May. 100(5):810-2. [Medline].
Voigt K, Yasargil MG. Cerebral cavernous haemangiomas or cavernomas. Incidence, pathology, localization, diagnosis, clinical features and treatment. Review of the literature and report of an unusual case. Neurochirurgia (Stuttg). 1976 Mar. 19(2):59-68. [Medline].
Waltimo O. The relationship of size, density and localization of intracranial arteriovenous malformations to the type of initial symptom. J Neurol Sci. 1973 May. 19(1):13-9. [Medline].
Weber W, Kis B, Siekmann R, et al. Endovascular treatment of intracranial arteriovenous malformations with onyx: technical aspects. AJNR Am J Neuroradiol. 2007 Feb. 28(2):371-7. [Medline].
Wilkins RH. Natural history of intracranial vascular malformations: a review. Neurosurgery. 1985 Mar. 16(3):421-30. [Medline].
Size of AVM*
Eloquence of adjacent brain†
Pattern of venous drainage‡
Small (< 3 cm)
1
Noneloquent
0
Superficial only
0
Medium (3-6 cm)
2
Eloquent
1
Deep component
1
Large (>6 cm)
3
…
…
* Measure the largest diameter of the nidus of the lesion on angiography.
† Eloquent areas include sensorimotor, language, visual, thalamus, hypothalamus, internal capsule, brain stem, cerebellar peduncles, and deep cerebellar nuclei.
‡ The lesion is considered superficial only if all drainage is via the cortical drainage system.
David Altschul, MD Fellow in Endovascular Neurosurgery, Mt Sinai-Roosevelt Medical Center
David Altschul, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.
Michael L Smith, MD Assistant Professor, Department of Neurosurgery, New York University School of Medicine
Michael L Smith, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Neurological Surgeons, Congress of Neurological Surgeons
Disclosure: Nothing to disclose.
Grant P Sinson, MD, MD
Grant P Sinson, MD, MD is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Received salary from Medscape for employment. for: Medscape.
Brian H Kopell, MD Associate Professor, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai
Brian H Kopell, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Neurological Surgeons, American Society for Stereotactic and Functional Neurosurgery, Congress of Neurological Surgeons, International Parkinson and Movement Disorder Society, North American Neuromodulation Society
Disclosure: Received consulting fee from Medtronic for consulting; Received consulting fee from Abbott Neuromodulation for consulting.
Duc Hoang Duong, MD Professor, Chief Physician, Departments of Neurological Surgery and Neuroscience, Epilepsy Center, Charles Drew University of Medicine and Science
Duc Hoang Duong, MD is a member of the following medical societies: American Neurological Association, Congress of Neurological Surgeons, North American Skull Base Society
Disclosure: Nothing to disclose.
Intracranial Arteriovenous Malformation
Research & References of Intracranial Arteriovenous Malformation|A&C Accounting And Tax Services
Source
0 Comments